Cytosorbents (CTSO) Set to Announce Quarterly Earnings on Thursday

Cytosorbents (NASDAQ:CTSO) will announce its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Cytosorbents (NASDAQ:CTSO) last released its earnings results on Thursday, March 14th. The medical research company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. The company had revenue of $8.67 million for the quarter, compared to analysts’ expectations of $9.29 million. Cytosorbents had a negative net margin of 78.43% and a negative return on equity of 120.24%. On average, analysts expect Cytosorbents to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cytosorbents Stock Performance

Shares of Cytosorbents stock opened at $0.93 on Wednesday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.51 and a current ratio of 1.77. The company has a fifty day moving average of $0.91 and a 200 day moving average of $1.12. The company has a market capitalization of $50.63 million, a P/E ratio of -1.46 and a beta of 0.62. Cytosorbents has a fifty-two week low of $0.78 and a fifty-two week high of $4.29.

Analysts Set New Price Targets

Several research firms recently issued reports on CTSO. StockNews.com started coverage on Cytosorbents in a research report on Thursday, May 2nd. They set a “hold” rating for the company. HC Wainwright reiterated a “neutral” rating and set a $1.00 price objective on shares of Cytosorbents in a research report on Tuesday.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.